MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains [Seeking Alpha]
MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong sell" rating.
MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM Exit - What's Changed [Yahoo! Finance]
MBX Biosciences (NASDAQ:MBX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "sell" rating and a $18.00 price target on the stock.
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus [Yahoo! Finance]